Stanford University
Showing 711-720 of 1,766 Results
-
Patrick David Hsu
Assistant Professor of Pathology
BioPatrick Hsu is Co-Founder of the Arc Institute and Assistant Professor of Pathology at Stanford University. The Hsu lab works at the intersection of biology and machine learning to develop technologies for biological and therapeutic design. Recent contributions include the Evo series of genome foundation models and the first universally programmable DNA recombinases. Patrick received A.M. and Ph.D. degrees from Harvard University and the Broad Institute of MIT and Harvard, where he was an early pioneer of CRISPR-Cas9 technologies for genome editing. His research has been recognized by awards from the New York Times, The Atlantic, Forbes, MIT Technology Review, Vox, Rainwater Foundation, and Amgen. He serves on the scientific advisory board of Amgen and the board of Stylus Medicine, and cofounded Fast Grants for rapid science funding.
-
Aaron Hsueh
Professor of Obstetrics and Gynecology (Reproductive and Stem Cell Biology), Emeritus
Current Research and Scholarly InterestsHormonal regulation of ovarian function; gonadotropin receptors and related genes, bioinformatic ananlyses of polypeptide hormones and receptors, follicle recruitment and GDF-9; analysis of oocyte and ovarian-expressed genes.
-
Yang Hu, MD, PhD
Professor of Ophthalmology
Current Research and Scholarly InterestsThe ultimate goal of the laboratory is to develop efficient therapeutic strategies to achieve CNS neural repair, through promoting neuroprotection, axon regeneration and functional recovery.
More specifically, we study retinal ganglion cell (RGC) and optic nerve in various optic neuropathies including traumatic, glaucomatous and inflammatory optic nerve injuries to fully understand the molecular mechanisms of CNS neurodegeneration and axon regeneration failure. -
KC Huang
LeRa Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsHow do cells determine their shape and grow?
How do molecules inside cells get to the right place at the right time?
Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations. -
Ngan F. Huang
Associate Professor of Cardiothoracic Surgery (Cardiothoracic Surgery Research) and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsDr. Huang's laboratory aims to understand the chemical and mechanical interactions between extracellular matrix (ECM) proteins and pluripotent stem cells that regulate vascular and myogenic differentiation. The fundamental insights of cell-matrix interactions are applied towards stem cell-based therapies with respect to improving cell survival and regenerative capacity, as well as engineered vascularized tissues for therapeutic transplantation.
-
Possu Huang
Assistant Professor of Bioengineering
Current Research and Scholarly InterestsProtein design: molecular engineering, method development and novel therapeutics
-
Ting-Ting Huang
Associate Professor (Research) of Neurology (Adult Neurology), Emerita
Current Research and Scholarly InterestsWe study the role of oxygen free radicals in oxidative tissue damage and degeneration. Our research tools include transgenic and knockout mice and tissue culture cells for in vitro gene expression.
-
Andrew D. Huberman
Associate Professor of Neurobiology and, by courtesy, of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsAndrew Huberman is a tenured associate professor of neurobiology and of ophthalmology at Stanford University School of Medicine, where he directs the Huberman Lab. After earning his B.A. from the University of California, Santa Barbara and completing M.A. and Ph.D. degrees in neuroscience at UC Berkeley and UC Davis, he conducted post-doctoral work at Stanford.
-
Adrian Hugenmatter
Director of Protein Engineering, Sarafan ChEM-H
BioDr. Adrian Hugenmatter joined ChEM-H as Director of Protein Engineering in 2021. In his role, Dr. Hugenmatter heads the Protein Engineering Laboratory at the Nucleus and is responsible for the development of therapeutic proteins at the Innovative Medicines Accelerator (IMA). Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Technology in Zurich (ETH Zurich, Switzerland), where he gained initial experience in the fields of enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he moved to the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Dr. Hugenmatter then worked for more than a decade as a researcher and team leader at Roche. During this time, he was involved in the development and optimization of several antibody lead candidates for therapeutic applications in neuroscience and oncology.
